Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Piper Sandler Initiates Coverage On Myriad Genetics with Neutral Rating, Announces Price Target of $23

Author: Benzinga Newsdesk | December 21, 2023 06:36am

Piper Sandler analyst John Peterson initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Neutral rating and announces Price Target of $23.

Posted In: MYGN